Court Grants Final Approval to Roundup™ Class Settlement

via Business Wire
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
  • Class settlement and the U.S. Supreme Court ruling are mutually reinforcing pillars in multi-pronged strategy to significantly contain the litigation
  • Monsanto will continue to vigorously defend cases and apply the Durnell ruling

Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy designed to significantly contain the Roundup™ litigation.

“The Court's final approval is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup™ litigation,” said Bill Anderson, CEO at Bayer.

The class approval decision follows closely on the heels of the unanimous defense verdict in Aretino, the first case to go to trial since the U.S. Supreme Court’s Durnell decision. Plaintiffs failed to prove design defect, fraud and negligence claims at trial, after the Court ruled their failure-to-warn claims were preempted by Durnell. This result validates Monsanto’s argument that these claims cannot be proven given that EPA and every other major regulatory body worldwide that has assessed such products, has found they can be used safely and are not carcinogenic. Glyphosate-based herbicides are critical tools that farmers rely on to produce affordable food and feed the world.

The company expects the number of opt outs to be manageable and amount to a very low percentage of current and potential future claims. Further, while a portion of the opt out claimants may pursue claims through the court system, many may not. Any plaintiff who chooses to litigate will face the burdens of both establishing that they have viable claims post-Durnell and ultimately proving them to a judge and jury. Monsanto believes the company is adequately provisioned to manage the remaining litigation.

About the class program

Monsanto pursued the class settlement to significantly contain the litigation, and the settlement agreement does not contain any admission of liability or wrongdoing. The Supreme Court ruling should foreclose any present or future claims based on failure-to-warn theories, the central theory in the litigation to date, including claims by opt outs from the class. The class settlement, in turn, provides a long-term claims program that will resolve present and future NHL injury claims, regardless of the legal theory on which they are based.

To fund the class settlement, Monsanto will make declining capped annual payments for up to 21 years totaling up to 7.25 billion U.S. dollars, inclusive of payments already made. The long-term payment stream will provide both greater certainty and control regarding litigation costs for current claims and future claimants.

The settlement includes plaintiffs who allege exposure to Roundup™ prior to February 17, 2026, and:

  • have a medical diagnosis of NHL now; or
  • receive a medical diagnosis of NHL before the end of a 16-year period following the effective date of the agreement.

Any appeal of the Court’s final approval order would pause further Monsanto payments until such appeals are exhausted. Monsanto believes the Court’s thoughtful and well-reasoned final approval order provides a very strong foundation supporting the class settlement, if the approval order is appealed, and the company will work together with class counsel to defend any challenges.

Find more information at www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article